MAPT and Alzheimer disease: For a targeted readout of AD-type 3/4R tau, we ran the same analyses using the AD-tailored temporal meta ROI, showing consistent group differences between AD patients and PSP, HC and α-syn patients when using the temporo-orbital WM reference (Fig. 5D) or the inferior cerebellar GM reference (Fig. 5E), yet standardized group differences were overall larger for AD patients vs. HC and disease controls when using the inferior cerebellar GM reference (Fig. 5F).